Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Jeollabuk-do, Korea, Republic of Clinical Trials

A listing of Jeollabuk-do, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (19) clinical trials

Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab

The study is designed as a prospective, observational study to assess the effect of adalimumab on health-related quality of life (QoL) and work productivity in patients with rheumatoid arthritis (RA) in Korea

Phase N/A

0.0 miles

Learn More »

Observational Study of Pertuzumab Safety in Participants With Breast Cancer

This Phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) will evaluate the safety of pertuzumab in approximately 3000 participants with metastatic or locally unresectable recurrent breast cancer who have never received chemotherapy or anti-human epidermal growth factor receptor 2 (HER2) therapy for their metastatic disease with HER2 positivity in ...

Phase N/A

0.0 miles

Learn More »

An Observational Study of Herceptin SC Safety in Breast Cancer

This is a phase IV, prospective, multicenter, observational study (regulatory post-marketing surveillance) in approximately 600 patients who are to receive Herceptin SC (trastuzumab, subcutaneous administration) per approved local labeling. Patients will be under observation according to standard of care in Korea.

Phase N/A

0.0 miles

Learn More »

An Observational Study of Kadcyla Safety in Breast Cancer

This is a phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) in approximately 3,000 patients who are to receive Kadcyla (trastuzumab emtansine). Patients with HER2-positive, unresectable locally advanced or metastatic breast cancer, who have received prior treatment with trastuzumab and a taxane, and administered Kadcyla infusion at physician's discretion ...

Phase N/A

0.0 miles

Learn More »

A Study of Atezolizumab (Tecentriq ) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.

Phase N/A

0.0 miles

Learn More »

A clinical trial seeking patients for a research study for the treatment of Chronic renal failure

The number of ESRD patients is growing at a much faster rate than the total population, with almost 1,000 (941.7) ESRD patients per one million as of 2006. The ESRD prevalence in Korea is ranked as high as 10th globally. The most common underlying diseases of ESRD in Korea include ...

Phase N/A

7.38 miles

Learn More »

XIENCE Xpedition/Alpine in Routine Clinical Practice

The purpose of this study is to evaluate effectiveness and safety of XIENCE xpedition/Alpine in Routine Clinical Practice

Phase N/A

7.38 miles

Learn More »

Effect and Efficacy of Onyx Zotarolimus-eluting Stent for Coronary Atherosclerosis

Secondary endpoints are Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI (percutaneous coronary intervention), Target vessel failure Composite rate of cardiac death and any MI, 3 years Composite rate of all death and any MI Composite rate of all death, any MI, ...

Phase N/A

7.38 miles

Learn More »

A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs

Post-marketing surveillance study to evaluate the real world safety and effectiveness of Viekira/ Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) administered under a normal, routine treatment practice by Korean patients with Hepatitis C.

Phase N/A

7.38 miles

Learn More »

Korean Post-marketing Surveillance for Xeljanz

The objective of this study is to identify any problems and questions with respect to the safety and efficacy of Xeljanz during the post-marketing period as required by the regulation of MFDS.

Phase N/A

7.38 miles

Learn More »